Navigation Links
Less than half of patients with MS continually adhere to drug therapies for treatment: Study
Date:5/10/2011

TORONTO, Ont., May 11, 2011 Disease-modifying drugs (DMDs) are injected medications used to slow the progression of multiple sclerosis (MS), and have been shown to reduce the frequency and severity of relapses. But according to a new study led by St. Michael's Hospital and the Institute for Clinical Evaluative Sciences (ICES), adherence to all DMDs is low, with less than half of patients, or 44 per cent, continually adherent after two years.

"There are a number of reasons why adherence to therapies of proven value might be low," says Dr. Paul O'Connor, director of the MS Clinic at St. Michael's Hospital. "These drugs don't work in everyone and some patients may stop them because they don't feel they are experiencing benefits. In some cases, patients may stop treatment because of side-effects. It is important that patients understand the need for continuing treatment in order to prevent some of the long-term consequences of MS."

The study, published in the May edition of The Canadian Journal of Neurological Sciences, aimed to determine differential adherence to these drugs in Ontario given that they are each marketed as differential efficacy, side effects, or convenience.

The study found:

  • 682 Ontarians filling prescriptions through Ontario's Public Drug Programs were newly treated with a DMD for MS between April 2006 and March 2008
  • Although DMDs differ with respect to frequency of injection, costs and side-effect profiles, there is no indication that adherence to these medications varies substantially in Ontario
  • Despite their efficacy, adherence to all DMDs is low, with less than half of patients (44 per cent) continually adherent after 2 years.

"This study shows that adherence to treatment with DMDs is low, which is concerning given their proven effectiveness in slowing the progression of MS. We need to increase the appreciation of the long-term benefits of these medications to ensure that MS patients are receiving the best treatment available," says co-author Tara Gomes, an epidemiologist at ICES.

The use of these drug therapies for the treatment of MS has risen 30 per cent between 2002 and 2007, with associated costs rising from $187 to $287 million in Canada.


'/>"/>

Contact: Julie Saccone
sacconej@smh.ca
416-864-5047
St. Michael's Hospital
Source:Eurekalert

Related medicine news :

1. Depression associated with poor medication adherence in patients with chronic illnesses
2. Vitamin D deficiency in pneumonia patients associated with increased mortality
3. Study Questions Overuse of Colonoscopy in Medicare Patients
4. Smokers undergo the same changes in gene expression as patients with COPD
5. New test could give SLE patients a more tolerable life
6. Most Leukemia Patients Recover From Chemo Brain After Transplant: Study
7. Many Dialysis Patients Short on Health Literacy
8. Families need to know more about feeding tubes for elderly dementia patients
9. U of A study finds ways to help end dry mouth in cancer patients
10. Susceptibility-weighted imaging can improve detection of and treatment for stroke patients
11. Low-dose chest CT effective in reducing radiation for evaluation of cardiothoracic surgery patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... ... June 28, 2017 , ... The ... program for mid-market executives as a kick-off to the fifth annual CEO Connection ... 2017 on the University of Pennsylvania campus, followed by the two-day convention, which ...
(Date:6/28/2017)... ... June 28, 2017 , ... Canadian Zeolite Corp. (the ... two year study conducted by the University of Saskatchewan in partnership with PotashCorp, ... potash brine-impacted groundwater. As a part of the study, batch adsorption experiments were ...
(Date:6/28/2017)... VA (PRWEB) , ... June 28, 2017 , ... ... protection assistance and financial consultations to communities in northern Virginia and DC, is ... to help provide for patients with Alzheimer’s and other disorders that lead to ...
(Date:6/27/2017)... ... June 27, 2017 , ... Nearly 70 percent ... data released today by the American Society for Dermatologic Surgery (ASDS). ... percentage of consumers considering a cosmetic medical procedure has doubled since 2013. , ...
(Date:6/27/2017)... ... 27, 2017 , ... Salucro, the cloud-based payment platform that ... hospitals and provider groups, has announced that it will now offer Parasail’s payment ... a San Francisco health-finance startup that has launched a series of tech-based products ...
Breaking Medicine News(10 mins):
(Date:6/16/2017)... , June 16, 2017 Datascope Corp. is voluntarily performing ... Corp. for a potential electrical test failure code.     ... PART NUMBER ... CS300 IABP 0998-UC-0446HXX; ... This ...
(Date:6/13/2017)... Ind. , June 13, 2017 Zimmer Biomet ... musculoskeletal healthcare, today announced that the U.S. Food and Drug ... dated June 3, 2015 relating to its Zhejiang, ... "The successful clearance of the ... manufacturing facility is a measure of the progress ...
(Date:6/9/2017)... , June 9, 2017 More than ... further effort to help spread lessons learned from clinical ... International Diabetes Federation (IDF) and Eli Lilly and Company ... the second phase of the Bringing Research in Diabetes ... their commitment to helping people with diabetes effectively manage ...
Breaking Medicine Technology: